MedTrace Logo

HRR as a Novel Biomarker in Sjögren's Syndrome

NCT05633524 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89

Last updated 2022-12-02

No results posted yet for this study

Summary

Sjögren's syndrome (SS) is an autoimmune disorder characterized by chronic salivary and lacrimal gland dysfunction leading to dry mouth (xerostomia) and dry eye (xerophthalmia) sensation (1). Although dry mouth and dry eye are the main symptoms, the disease may influence many organs and systems. Diagnosis is made with ocular surface staining scores, anti-SS-A/SS-B auto-antibody positivity, and minor salivary gland biopsy (2). The Complete blood count (CBC) is a simple, inexpensive, accessible, and routinely used laboratory parameter that can be linked to oxidative stress, inflammation and microvascular flow resistance. Parameters include NLR and PLR values may be calculated by using CBC parameters (3). Neutrophil/lymphocyte ratio is used as an inflammatory marker in the diagnosis and prognosis of many cardiovascular diseases, malignancies, and infections (4-6). Peripheral inflammatory biomarkers of hematologic indices had been suggested by numerous studies to play a role during SS onset and progression.

Conditions

  • Sjögren's Syndrome

Interventions

OTHER

blood sample analysis

All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed

Sponsors & Collaborators

  • Tianjin Eye Hospital

    lead OTHER

Principal Investigators

  • Yan Wang · Tianjin Eye Hospital and Eye Institute, Nankai University Affiliated Eye Hospital

Eligibility

Min Age
45 Years
Max Age
67 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-29
Primary Completion
2022-11-21
Completion
2022-11-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05633524 on ClinicalTrials.gov